Main description:

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors.

Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike.

2018 BMA Medical Book Awards Highly Commended in Oncology

Contents:

Section I. Immunological Features of Brain Tumors 1. An Introduction to Immunotherapy in the Treatment of Brain Tumors 2. Immune Constitution of Patients With Brain Tumors 3. The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression 4. The Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors 5. Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy

Section II. Studying Brain Tumor Immunotherapy 6. Preclinical Immunotherapeutic Animal Models for Brain Tumors 7. Imaging Studies in Immunotherapy 8. Immunotherapy Clinical Trials in Neuro-Oncology

Section III. Experimental Brain Tumor Immunotherapies 9. Peptide-Specific Vaccines 10. Immunotoxin Therapy for Brain Tumors 11. Checkpoint Blockade Immunotherapy for Glioblastoma: Progress and Challenges 12. Dendritic Cell Therapy for Brain Tumors 13. Adoptive Immunotherapy Against Brain Tumors 14. Chimeric Antigen Receptor Therapy of Brain Tumors